Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Taletrectinib adipate by Nuvation Bio for Solid Tumor: Likelihood of Approval
Taletrectinib adipate is under clinical development by Nuvation Bio and currently in Phase I for Solid Tumor. According to GlobalData,...
Taletrectinib adipate by Nuvation Bio for Colorectal Cancer: Likelihood of Approval
Taletrectinib adipate is under clinical development by Nuvation Bio and currently in Phase I for Colorectal Cancer. According to GlobalData,...
NUV-1511 by Nuvation Bio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
NUV-1511 by Nuvation Bio for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
NUV-1511 by Nuvation Bio for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
NUV-1511 by Nuvation Bio for Peritoneal Cancer: Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
NUV-1511 by Nuvation Bio for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
NUV-1511 by Nuvation Bio for Fallopian Tube Cancer: Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
NUV-1511 by Nuvation Bio for Ovarian Cancer: Likelihood of Approval
NUV-1511 is under clinical development by Nuvation Bio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
NUV-868 by Nuvation Bio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
NUV-868 by Nuvation Bio for Peritoneal Cancer: Likelihood of Approval
NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
NUV-868 by Nuvation Bio for Pancreatic Cancer: Likelihood of Approval
NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
NUV-868 by Nuvation Bio for Ovarian Cancer: Likelihood of Approval
NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Taletrectinib adipate by Nuvation Bio for Non-Small Cell Lung Cancer: Likelihood of Approval
Taletrectinib adipate is under clinical development by Nuvation Bio and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to...